07:00 , Jul 19, 2010 |  BC Week In Review  |  Clinical News

Amplimexon imexon: Phase II data

In the double-blind, U.S. Phase II AMP-019 trial in 142 patients, Amplimexon plus Gemzar gemcitabine missed the primary endpoint of significantly improving OS vs. placebo plus Gemzar (p=0.64). AmpliMed said the trial required a 40%...
23:06 , Jul 12, 2010 |  BC Extra  |  Clinical News

AmpliMed restructuring after Amplimexon miss

AmpliMed Corp. (Tucson, Ariz.) will reduce headcount by 10 (63%) to 6, including part-time employees, and consider strategic options after Amplimexon imexon missed the primary endpoint in the Phase II AMP-019 trial to treat advanced...
07:00 , Sep 15, 2008 |  BC Week In Review  |  Company News

AmpliMed, Handok Pharmaceuticals Co. Ltd. deal

Handok received exclusive, Korean rights to AmpliMed's Amplimexon imexon to treat cancer. AmpliMed will receive an undisclosed upfront fee and is eligible for development and regulatory milestones. The small molecule cyanoaziridine is in Phase II...
07:00 , May 5, 2008 |  BC Week In Review  |  Clinical News

Amplimexon imexon: Phase II started

AmpliMed began a double-blind, U.S. Phase II trial to evaluate 1,000 mg/m 2 of IV gemcitabine with or without 875 mg/m 2 of IV Amplimexon in 124 treatment-naïve patients. Gemzar gemcitabine is marketed by Eli...
08:00 , Jan 7, 2008 |  BC Week In Review  |  Clinical News

Amplimexon imexon: Phase I/II data

In the Phase I/II AMP-005 trial in 68 patients, median overall survival for Amplimexon plus dacarbazine was 11.7 months. The company said historical survival data for patients receiving dacarbazine is 8 months for controls. In...
08:00 , Nov 20, 2006 |  BC Week In Review  |  Clinical News

Amplimexon imexon: Phase I data

In a Phase I trial in 49 patients, Amplimexon was well tolerated and the maximum tolerated dose was 875 mg/m 2/day. Patients received Amplimexon doses ranging from 20-1000 mg/m 2/day as a 30 minute infusion....
07:00 , Sep 18, 2006 |  BC Week In Review  |  Clinical News

Amplimexon imexon: Interim Phase I/II data

Interim data from 27 evaluable patients in an open-label, U.S. Phase I/II trial showed that Amplimexon plus dacarbazine (DTIC) treatment led to a partial response in 5 patients and 7 patients had stable disease for...
07:00 , May 1, 2006 |  BC Week In Review  |  Clinical News

Benzimate: Phase I started

AmpliMed started a U.S. Phase I trial in about 50 patients to treat advanced refractory cancer. AmpliMed Corp. , Tucson, Ariz.   Product: Benzimate   Business: Cancer   Molecular target: NA   Description: Apoptotic anti-cancer...
07:00 , Apr 3, 2006 |  BC Week In Review  |  Clinical News

Amplimexon imexon: Phase Ib/II start

AmpliMed began the open-label, dose-escalation, U.S. Phase Ib portion of a Phase Ib/II trial with Amplimexon as a monotherapy in 40-50 previously treated MM patients. The trial will continue into the Phase II portion once...
08:00 , Jan 16, 2006 |  BC Week In Review  |  Clinical News

Amplimexon imexon regulatory update

EMEA granted Orphan Drug designation to Amplimexon to treat ovarian cancer. The small molecule cyanoaziridine already has U.S. Orphan Drug designation for this indication. AmpliMed Corp. , Tucson, Ariz.   Product: Amplimexon imexon   Business:...